Nanalysis Scientific Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Nanalysis Scientific şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-11.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-11.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Oct 28

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 19

Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 12

Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet

Mar 24

Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth

Feb 08

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NSCI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NSCI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Nanalysis Scientific Piyasaya Karşı Temettü Getirisi

NSCI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NSCI)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (NSCI) (3 yıla kadar)	n/a

Önemli Temettü: NSCI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NSCI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NSCI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NSCI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Nanalysis Scientific Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.062 loss in 3Q 2023)

Nanalysis Scientific Corp. to Report Q3, 2024 Results on Nov 21, 2024

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Second quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 2Q 2023)

Nanalysis Scientific Corp. to Report Q2, 2024 Results on Aug 28, 2024

High number of new and inexperienced directors

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.042 loss in 1Q 2023)

Nanalysis Scientific Corp. to Report Q1, 2024 Results on May 29, 2024

Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.098 loss in FY 2022)

Nanalysis Scientific Corp., Annual General Meeting, Jun 26, 2024

Nanalysis Scientific Corp. to Report Q4, 2023 Results on Apr 25, 2024

Nanalysis Scientific Corp. Announces Resignation of Kham Lin as A Director

Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances

Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet

Nanalysis Scientific Corp. has completed a Composite Units Offering in the amount of CAD 5 million.

Nanalysis Scientific Corp. announced that it expects to receive CAD 1 million in funding

Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth

Nanalysis Scientific Corp. Provides Earnings Guidance for the Fourth Quarter 2023

We Think Nanalysis Scientific (CVE:NSCI) Has A Fair Chunk Of Debt

Third quarter 2023 earnings released: CA$0.06 loss per share (vs CA$0.026 loss in 3Q 2022)

Nanalysis Scientific Corp. to Report Q3, 2023 Results on Nov 29, 2023

Would Nanalysis Scientific (CVE:NSCI) Be Better Off With Less Debt?

Second quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.024 loss in 2Q 2022)

Nanalysis Scientific Corp. to Report Q2, 2023 Results on Aug 24, 2023

Nanalysis Scientific Corp. to Report Q1, 2023 Results on May 25, 2023

Nanalysis Scientific Corp. announced that it has received CAD 4.1287 million in funding

Full year 2022 earnings released: CA$0.10 loss per share (vs CA$0.025 loss in FY 2021)

Nanalysis Scientific Corp.'s (CVE:NSCI) Price Is Right But Growth Is Lacking

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Third quarter 2022 earnings released

Nanalysis Scientific Corp. to Report Q3, 2022 Results on Nov 29, 2022

Price target decreased to CA$2.75

High number of new and inexperienced directors

Nanalysis Scientific Corp. Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Price target decreased to CA$2.75

Nanalysis Scientific Corp. to Report Q2, 2022 Results on Aug 25, 2022

Nanalysis Scientific Corp. Announces Executive Changes

Is Nanalysis Scientific (CVE:NSCI) Weighed On By Its Debt Load?

Nanalysis Scientific Corp. Announces Appointment of Kham Lin as New Director

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.007 loss in 1Q 2021)

Nanalysis Scientific Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: CA$0.03 loss per share (vs CA$0.056 loss in FY 2020)

High number of new and inexperienced directors

Nanalysis Scientific Corp. to Report Fiscal Year 2021 Results on Apr 28, 2022

Nanalysis Scientific Corp. has completed a Follow-on Equity Offering in the amount of CAD 10.725 million.

Health Check: How Prudently Does Nanalysis Scientific (CVE:NSCI) Use Debt?

Nanalysis Scientific Corp. (TSXV:NSCI) completed the acquisition of K'(Prime) Technologies Inc.

Nanalysis Scientific Corp. announced that it expects to receive CAD 0.2025 million in funding

High number of new and inexperienced directors

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.017 loss in 3Q 2020)

Second quarter 2021 earnings released

Nanalysis Scientific Corp. has completed a Composite Units Offering in the amount of CAD 8.00004 million.

Nanalysis Scientific Corp. announced that it has received CAD 1.797638 million in funding

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.014 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.056 loss per share (vs CA$0.03 loss in FY 2019)

Is Nanalysis Scientific (CVE:NSCI) Using Debt Sensibly?

Nanalysis Scientific Corp. Signs Strategic OEM Partnership for Magnetic Resonance Electronics Sales

New 90-day high: CA$0.50

Nanalysis Scientific (CVE:NSCI) Has Debt But No Earnings; Should You Worry?

Third quarter 2020 earnings released: CA$0.017 loss per share

New 90-day low: CA$0.40

New 90-day low - CA$0.45

Earnings released

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin